ClinicalTrials.gov
public full text
Public Domain
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving lonafarnib together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lonafarnib when given together with temozolomide in treating patients with recurrent primary supratentorial glioma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma#908839
- Editorial: Innovative approaches in glioma therapy: exploring new therapeutic frontiers, volume II#438735
- Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma#245511
- Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma#1115245
- Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme#905894
Record · ID 911385
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive